Celltrion Reports Results of Truxima (biosimilar, rituximab) in P-III Study for Advanced Follicular Lymphoma in the US

 Celltrion Reports Results of Truxima (biosimilar, rituximab) in P-III Study for Advanced Follicular Lymphoma in the US

Celltrion Reports Results of CT-P13 SC (infliximab, biosimilar) in a Clinical Study for Rheumatoid Arthritis #EULAR2019

Shots:

  • The P-III study involves assessing of Truxima vs Rituxan in 140 patients with AFL for 40mos. across India, Japan, Russia, and the EU, including Germany and Spain
  • The P-III study results: @4yrs. OS (88% vs 93.4%); PFS (60.9% vs 54.7%); TTP (64.2% vs 60.9%), presented at ASH2019
  • Celltrion has launched Truxima in the US via Teva and is the first rituximab biosimilar in the US with an annual sale of $4.2B

Click here to read full press release/ article | Ref: Korea Biomed | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post